%PDF-1.4
%
80 0 obj
<>
endobj
77 0 obj
<>
endobj
138 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-04-09T16:30:10Z
2024-03-28T08:35:11-07:00
QuarkXPressª 4.11: AdobePS 8.6 (219)
2024-03-28T08:35:11-07:00
application/pdf
Heather
2002-330.may
uuid:4d9632ac-1dd2-11b2-0a00-090a27bd7200
uuid:4d9632af-1dd2-11b2-0a00-880000000000
endstream
endobj
66 0 obj
<>
endobj
67 0 obj
<>
endobj
81 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
9 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
12 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
20 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
33 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
46 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
54 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
168 0 obj
[172 0 R]
endobj
169 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 61 714.5293 Tm
[(3.)-875.1 (Eilat D, Hochber)17.7 (g M, Fischel R, Laskov R. )54.8 (Antibodies to RNA)]TJ
1.675 -1.25 Td
[(from autoimmune NZB/NZW)-257.3 (mice recognize a similar antigenic)]TJ
0 -1.25 TD
[(determinant and show lar)17.7 (ge idiotypic diversity)64.9 (. Proc Natl )54.8 (Acad Sci)]TJ
0 Tc 0 Tw T*
[(USA)-220.1 (1982;79:3818-22.)]TJ
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4.)-875.1 (Lamon EW)91.7 (, Bennett JC. )54.8 (Antibodies to homologous RNA)-220.2 (in the)]TJ
1.675 -1.25 Td
(rabbit following stimulation by exogenous RNA. Proc Soc Exp)Tj
0 Tc T*
(Biol Med 1970;134:968-70.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(5.)-875.1 (W)39.8 (ilusz J, Keene JD. )54.8 (Autoantibodies specific for U1 RNA)-220.2 (and)]TJ
1.675 -1.25 Td
(initiator methionine tRNA. J Biol Chem 1986;261:5467-72.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (Deutscher SL, Keene JD. )54.8 (A)-220.1 (sequence-specific conformational)]TJ
1.675 -1.25 Td
[(epitope on U1 RNA)-220.2 (is recognized by a unique autoantibody)64.8 (. Proc)]TJ
T*
[(Natl )54.8 (Acad Sci USA)-220.2 (1988;85:3299-303.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (van )17.7 (V)110.8 (enrooij )17.7 (WJ, Hoet R, Castrop R, et al. )54.8 (Anti-\(U1\) small nuclear)]TJ
1.675 -1.25 Td
[(RNA)-220.2 (antibodies in anti-small nuclear ribonucleoprotein sera from)]TJ
T*
(patients with connective tissue diseases. J Clin Invest)Tj
0 Tc 0 Tw T*
(1990;86:2154-60.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Hoet RM, De )17.7 (W)79.9 (eerd P)110.7 (, Gunnewiek JK, et al. Epitope regions on U1)]TJ
1.675 -1.25 Td
[(small nuclear RNA)-220.2 (recognized by anti-U1RNA-specific )]TJ
T*
(autoantibodies. J Clin Invest 1992;90:1753-62.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Boulanger C, Chabot B, Menard HA, et al. )54.8 (Autoantibodies in)]TJ
1.675 -1.25 Td
(human anti-Ro sera specifically recognize deproteinized hY5 Ro)Tj
T*
(RNA. Clin Exp Immunol 1995;99:29-36.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Bunn CC, Mathews MB. )54.8 (Autoreactive epitope defined as the anti-)]TJ
2.175 -1.25 Td
[(codon region of alanine transfer RNA. Science 1987;238:1)36.8 (169-9.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Becker HF)79.7 (, Corda )36.8 (Y)128.9 (, Mathews MB, et al. Iosine and )]TJ
2.1381 -1.25 Td
(N1-methylinosine within a synthetic oligomer mimicking the )Tj
T*
[(anticodon loop of human tRNA)-220.2 (\(Ala\) are major epitopes for )]TJ
T*
[(anti-PL-12 myositis autoantibodies. RNA)-220.2 (1999;5:865-75.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (Brouwer R, )17.7 (V)59.8 (ree Egberts )17.7 (W)91.8 (, Jongen PH, et al. Frequent occurrence)]TJ
2.175 -1.25 Td
[(of anti-tRNA)-220.2 (\(His\) autoantibodies that recognize a conformational)]TJ
T*
[(epitope in sera of patients with myositis. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1998;41:2059-67.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (Uchiumi )17.7 (T)74 (,)-0.1 ( )17.7 (T)35 (raut RR, Elkon K, Kominami R. )54.8 (A)-220.1 (human )]TJ
2.175 -1.25 Td
(autoantibody specific for a unique conserved region of 28S )Tj
T*
[(ribosomal RNA)-220.2 (inhibits the interaction of elongation factors 1a and)]TJ
T*
(2 with ribosomes. J Biol Chem 1991;266:2054-62.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Sun )36.8 (Y)128.9 (,)-0.1 ( Fong KY)128.8 (, Chung MC, )36.8 (Y)99.8 (ao ZJ. Peptide mimicking antigenic)]TJ
2.175 -1.25 Td
[(and immunogenic epitope of double-stranded DNA)-220.2 (in systemic)]TJ
T*
(lupus erythematosus. Int Immunol 2001;13:223-32.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Hoet RM, Koornneef I, de Rooij DJ, et al. Changes in anti-U1)]TJ
2.175 -1.25 Td
[(RNA)-220.2 (antibody levels correlate with disease activity in patients with)]TJ
T*
[(systemic lupus erythematosus overlap syndrome. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1992;35:1202-10.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (T)69.9 (sai DE, Kenan DJ, Keene JD. In vitro selection of RNA)-220.2 (epitopes)]TJ
2.175 -1.25 Td
[(using autoimmune patients serum. J Immunol 1993;150:1)36.8 (137-45.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (Hirokawa K, )17.7 (T)69.9 (akasaki )36.8 (Y)128.9 (,)-0.1 ( )17.7 (T)69.9 (akeuchi K, et al. )54.8 (Anti-TS1-RNA:)]TJ
2.175 -1.25 Td
(Characterization of a novel antibody against the sequence-specific)Tj
T*
[(RNA)-220.2 (by a random RNA)-220.2 (selection in patients with Sj\232gren\325)54.8 (s)]TJ
T*
(syndrome. J Rheumatol 2002;29:931-7.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Sharp GC, Irvin )17.7 (WS, )17.7 (T)69.9 (an EM, et al. Mixed connective tissue)]TJ
2.175 -1.25 Td
(disease syndrome associated with a specific antibody to an)Tj
T*
[(extractable nuclear antigen. )54.8 (Am J Med 1972;52:148-59.)]TJ
-2.175 -1.25 Td
[(19.)-875.1 (Ohtsuka E, Nonaka S, Shingu M, et al. Sj\232gren\325)54.8 (s syndrome and)]TJ
2.175 -1.25 Td
(mixed connective tissue disease. Clin Exp Rheumatol 1992;)Tj
0 Tc 0 Tw T*
(10:339-44.)Tj
-0.00011 Tc 0.02499 Tw 30.825 67.5 Td
[(20.)-875.1 (Kasukawa R, )17.7 (T)69.9 (ojo )17.7 (T)74 (, Miyawaki S. Mixed connective tissue disease)]TJ
2.175 -1.25 Td
(\321 preliminary diagnostic criteria. Jpn J Rheumatol 1988;1:263-7.)Tj
-2.175 -1.25 Td
[(21.)-875.1 (Smolen JS, Steiner G. Mixed connective tissue disease: to be or not)]TJ
2.175 -1.25 Td
[(to be? )54.8 (Arthritis Rheum 1998;41:768-77.)]TJ
-2.175 -1.25 Td
[(22.)-875.1 (Burdt MA, Hof)17.7 (fman R)54.8 (W)91.9 (, Deutscher SL, et al. Long-term outcome)]TJ
2.175 -1.25 Td
(in mixed connective tissue disease: longitudinal clinical and )Tj
T*
[(serological findings. )54.8 (Arthritis Rheum 1999;42:899-909.)]TJ
-2.175 -1.25 Td
[(23.)-875.1 (V)59.8 (itali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary)]TJ
2.175 -1.25 Td
[(criteria for the classification of Sj\232gren\325)54.8 (s syndrome. Results of a)]TJ
T*
(prospective concerted action supported by the European)Tj
T*
[(Community)64.9 (. )54.8 (Arthritis Rheum 1993;36:340-7.)]TJ
-2.175 -1.25 Td
[(24.)-875.1 (T)69.9 (an EM, Cohen )54.8 (AS, Fries JF)79.7 (, et al. )17.7 (The 1982 revised criteria for the)]TJ
2.175 -1.25 Td
[(classification of systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1982;25:1271-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(25.)-875.1 (Subcommittee for Scleroderma Criteria of the )54.8 (American)]TJ
2.175 -1.25 Td
[(Rheumatism )54.8 (Association Diagnostic and )17.7 (Therapeutic Criteria)]TJ
T*
(Committee. Preliminary criteira for the classification of systemic)Tj
T*
[(sclerosis \(scleroderma\). )54.8 (Arthritis Rheum 1980;23:581-90.)]TJ
-2.175 -1.25 Td
[(26.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
2.175 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-2.175 -1.25 Td
[(27.)-875.1 (Bohan )54.8 (A, Peter JB. Polymyositis and dermatomyositis \(first of 2)]TJ
2.175 -1.25 Td
(parts\). N Engl J Med 1975;292:344-7.)Tj
-2.175 -1.25 Td
[(28.)-875.1 (Ohosone )36.8 (Y)128.9 (, Ishida M, )17.7 (T)69.9 (akahashi )36.8 (Y)128.9 (, et al. Spectrum and clinical)]TJ
2.175 -1.25 Td
[(significance of autoantibodies against transfer RNA. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1998;41:1625-31.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(29.)-875.1 (Sharp GC. Diagnostic criteria for classification of MCTD. In:)]TJ
2.175 -1.25 Td
(Kasukawa R, Sharp GC, editors. Mixed connective tissue diseases)Tj
T*
[(and antinuclear antibodies. )54.8 (Amsterdam: Elsevier; 1987:23-32.)]TJ
-2.175 -1.25 Td
[(30.)-875.1 (Alarcon-Segovia D, )17.7 (V)59.8 (illareal M. Classification and diagnostic)]TJ
2.175 -1.25 Td
(criteria for mixed connective tissue disease. In: Kasukawa R, Sharp)Tj
T*
(GC, editors. Mixed connective tissue diseases and antinuclear )Tj
T*
[(antibodies. )54.8 (Amsterdam: Elsevier; 1987:33-40.)]TJ
-2.175 -1.25 Td
[(31.)-875.1 (Kahn MF)79.7 (, )54.8 (Appelboom )17.7 (T)74 (. Syndrome de Sharp. In: Kahn MF)79.7 (, Peltier)]TJ
2.175 -1.25 Td
[(AP)110.8 (, Meyer O, Piette JC, editors. Les maladies systemiques. 3rd ed.)]TJ
T*
(Paris: Flammarion; 1991:545-56.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (Kasukawa R, )17.7 (T)69.9 (ojo )17.7 (T)74 (, Miyawaki S. Preliminary diagnostic criteria)]TJ
2.175 -1.25 Td
(for classification of mixed connective tissue disease. In: Kasukawa)Tj
T*
(R, Sharp GC, editors. Mixed connective tissue diseases and )Tj
T*
[(antinuclear antibodies. )54.8 (Amsterdam: Elsevier; 1987:41-7.)]TJ
-2.175 -1.25 Td
[(33.)-875.1 (Chang )36.8 (YN, Kenan DJ, Keene JD, et al. Direct interactions between)]TJ
2.175 -1.25 Td
(autoantigen La and human immunodeficiency virus leader RNA. )Tj
0.00729 Tw T*
[(J V)59.8 (irol )-17.7 (1994;68:7008-20.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(34.)-875.1 (Keene JD, Query CC. Nuclear RNA-binding proteins. Prog Nucl)]TJ
2.175 -1.25 Td
(Acids Res Mol Biol 1991;41:179-202.)Tj
-2.175 -1.25 Td
[(35.)-875.1 (Pettersson I, )17.7 (W)79.9 (ang G, Smith EI, et al. )17.7 (The use of immunoblotting)]TJ
2.175 -1.25 Td
(and immunoprecipitation of \(U\) small nuclear ribonucleoproteins in)Tj
T*
(the analysis of sera of patients with mixed connective tissue disease)Tj
T*
[(and systemic lupus erythematosus. )54.8 (A)-220.1 (cross-sectional, longitudinal)]TJ
T*
[(study)64.9 (. )54.8 (Arthritis Rheum 1986;29:986-96.)]TJ
-2.175 -1.25 Td
[(36.)-875.1 (Snowden N, Hay E, Holt PJL, Berstein R. Clinical course of)]TJ
2.175 -1.25 Td
[(patients with anti-RNP)-238.2 (antibodies. J Rheumatol 1993;20:1256-8.)]TJ
-2.175 -1.25 Td
[(37.)-875.1 (de Rooji DJ, Habets )17.7 (WJ, van de Putte LB, et al. Use of recombinant)]TJ
2.175 -1.25 Td
[(RNP)-238.2 (peptides 70K and )54.8 (A)-220.1 (in an ELISA)-220.2 (for measurement of )]TJ
T*
(antibodies in mixed connective tissue disease: a longitudinal follow)Tj
0 Tc T*
[(up of 18 patients. )54.8 (Ann Rheum Dis 1990;49:391-5.)]TJ
ET
0 0 0 0 scn
420 777 137 -27 re
f*
408 770 150 -25 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/T1_1 1 Tf
-0.00011 Tc 8 0 0 8 54.5 35.9844 Tm
[(Ikeda, et al: )17.7 (Anti-TS1-RNA)-257.3 (in MCTD)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(1005)Tj
ET
0 0 0 0 scn
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
93 0 obj
<>
endobj
84 0 obj
<>
endobj
121 0 obj
<>
endobj
143 0 obj
<>
endobj
83 0 obj
<>
endobj
115 0 obj
<>stream
HyPTg